Drugs / KSO-0400
re-read 2 minutes ago

KSO-0400

Developed for
benign prostatic hyperplasia
Investigated by
Kissei Pharmaceutical Co., Ltd.

Trials 1

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT01222650 benign prostatic hyperplasia Kissei Pharmaceutical Co., Ltd. Completed No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as KSO-0400 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01222650